Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients

Indian Journal of Medical Research

Volumn 120, Issue 5, 2004, Pages 481-488

  Ersoy, Canan ^a   Imamoǧlu, Sazi ^a   Budak, Ferah ^a   Tuncel, Ercan ^a   Ertürk, Erdinç ^a   Oral, Barbaros ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Amlodipine; Insulin resistance; Leptin; Tumor necrosis factor alpha

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; INSULIN; LEPTIN; LONG ACTING DRUG; MONOVAS; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEG EDEMA; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; LIPIDS; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11044234746     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Reaven GM. Banting Lecture 1998. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14 173-94.
3. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 1994; 94 1543-9.
4. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor- mediated signal transduction. J Biol Chem 1997; 272: 971-6.
5. Halle M, Berg A, Northoff H, Keul J. Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exerc Immunol Rev 1998; 4: 77-94.
6. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related heperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997; 100: 2777-82.
7. Corica F, Allegra A, Corsonello A, Buemi M, Calapai G, Ruello A, et al. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects. Int J Obes Relat Metab Disord 1999; 23: 355-60.
8. Bakris GL. Pathogenesis of hypertension in diabetes. Diabetes Rev 1995; 3: 460-76.
9. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibitors improves insulin sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6 175-9.
10. Huupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992; 43: 365-8.
11. Harano Y, Kageyama A, Hirose J, Asakura Y, Yokota T, Ikebuchi M, et al. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 1995; 44: 315-9.
12. Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S46-52.
13. Hedner T, Samuelsson O, Lindholm L. Effects of antihypertensive therapy on glucose tolerance; focus on calcium antagonists. J Intern Med Suppl 1991; 735: 101-11.
14. Fukuzawa M, Satoh J, Ohta S, Takahashi K, Miyaguchi S, Qiang X, et al. Modulation of tumor necrosis factor-α production with anti-hypertensive drugs. Immunopharmacology 2000; 48: 65-74.
15. Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Horm Metab Res 2001; 33: 167-9.
16. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-83.
17. Bloomgarden ZT. American Diabetes Association 60th Scientific Sessions, 2000: nutrition, lipids, and alternative medicine. Diabetes Care 2000; 23: 1847-51.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Hotamisligil GS, Spiegelman BM. TNF-α, and the insulin resistance of obesity. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott-Raven; 1996 p. 554-60.
21. Sheu WHH, Lee WJ, Chang RL, Chen YT. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects. Clin Exp Hypertens 2000; 22: 595-606.
22. Demirbas B, Güler S, Cakir B, Culha C, Aral Y. Plasma tumor necrosis factor-alpha levels and insulin resistance in nondiabetic hypertensive subjects. Horm Res 2002; 58: 283-6.
23. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 52: 119-23.
24. Lechleitner M, Herold M, Dzien-Bischinger C, Hoppichler F, Dzien A. Tumour necrosis factor-alpha plasma levels in elderly patients with type 2 diabetes mellitus - observations over 2 years. Diabetes Med 2002; 19: 949-53.
25. Levy JR. Gyarmati J, Lesko JM, Adler RA, Stevens W. Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. Am J Physiol Endocrinol Metab 2000; 278: E892-901.
26. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.
27. Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens 1999; 21: 167-79.
28. Chou TC, Yang SP, Pei D. Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-gamma-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol 2002; 89: 157-63.
29. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2003; 27: 88-94.
30. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 859-62.
31. Zheng D, Jones JP, Usala SJ, Dohm GL. Differential expression of ob mRNA in rat adipose tissues in response to insulin. Biochem Biophys Res Commun 1996; 218: 434-7.
32. Wollheim CB, Sharp GW. Regulation of insulin release by calcium. Physiol Rev 1981; 61: 914-73.
33. Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic. subjects: a review. J Hypertens 1987; 5 (Suppl): S81-104.
34. Kumar N, Dey CS.Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J. Exp Biol 2002; 205: 3739-46.